ProCE Banner Activity

CE / CME

Pharmacotherapy of Schizophrenia

Multimedia
In this interactive recording of a live CCO webinar, John M. Kane, MD, discusses pharmacotherapy of schizophrenia and reviews the role of shared decision-making, considerations in balancing efficacy and tolerability, the role of maintenance treatment, whether long-acting formulations can help in reducing relapse risk, and when clozapine is indicated.

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Psychologists: 1.00 APA CE Credit

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurses: 1.00 Nursing contact hour

Social Workers: 1.00 ASWB ACE CE Credit

Released: February 15, 2022

Expiration: February 14, 2023

No longer available for credit.

Share

Faculty

John M. Kane

John M. Kane, MD

Professor of Psychiatry and Molecular Medicine
Zucker School of Medicine at Hofstra/Northwell
Hempstead, New York
Co-Director, Institute for Behavioral Science, Feinstein Institutes for Medical Research
Northwell Health
Glen Oaks, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Intra Cellular Therapies

Target Audience

This activity is intended for physicians, physician assistants, nurse practitioners, registered nurses, pharmacists, social workers, and psychologists engaged in the care of patients with schizophrenia.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Identify the role of shared decision-making
  • Discuss considerations in balancing efficacy and tolerability
  • Describe the role of maintenance treatment
  • Describe if long-acting formulations help in reducing relapse risk
  • Explain when is clozapine indicated

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

John M. Kane, MD

Professor of Psychiatry and Molecular Medicine
Zucker School of Medicine at Hofstra/Northwell
Hempstead, New York
Co-Director, Institute for Behavioral Science, Feinstein Institutes for Medical Research
Northwell Health
Glen Oaks, New York

John M. Kane, MD, has disclosed that he has received funds for research support from H. Lundbeck, Janssen, and Otsuka; has received consulting fees from Alkermes, Allergan, Dainippon Sumitomo, H. Lundbeck, Indivior, Intra-Cellular, Janssen, Johnson and Johnson, LB Pharmaceuticals, Merck, Minerva, Neurocrine, Otsuka, Reviva, Roche, Saladex, Sunovion, Takeda, and Teva; and has ownership interest in LB Pharmaceuticals and North Shore Therapeutics.

Staff Disclosure

Staff

Mark Christiansen, PhD, PA-C

Mark Christiansen, PA-C, has no relevant conflicts of interest to report.

Stephanie Filice, LICSW

Stephanie Filice, LCSW, has no relevant conflicts of interest to report.

Aditi Nadkarni, PhD

Aditi Nadkarni, PhD, has no relevant conflicts of interest to report.

Lisa Phipps, PharmD, PhD

Director, Science and Strategy, Neuroscience

Lisa Phipps, PharmD, PhD, has no relevant conflicts of interest to report.

Stephen Skiffington, PhD

Stephen Skiffington, PhD, has no relevant conflicts of interest to report.

Julie Skowronski, FNP-BC

Julie Skowronski, NP, has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Credit Designation

CCO designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-050-H01-P.

Type of Activity: Application

Upon successfully completing the post-test with a score of 70% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until February 14, 2023. PAs should only claim commensurate with the extent of their participation.

Continuing education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs.

This activity offers 1.0 continuing education credit for psychologists.

As a Jointly Accredited Organization, Clinical Care Options, LLC (CCO) is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. CCO maintains responsibility for this course. Social workers completing this course receive 1.0 clinical continuing education credit.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from February 15, 2022, through February 14, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the knowledge, competence, and performance of learners to assess diagnostic considerations and new and emerging therapies for the treatment of patients with schizophrenia.